NCT00346684View on ClinicalTrials.gov

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2006

Primary Completion Date

November 30, 2007

Conditions
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Interventions
DRUG

Rituximab

Trial Locations (1)

50931

University of Cologne, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00346684 - Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) | Biotech Hunter | Biotech Hunter